/

DNLI

Denali Therapeutics Inc.Pre-market

18.95−0.50 −2.57%USD

NasdaqGS · as of Oct 12, 16:00 ET · 15m delay

Open

19.30

Prev close

19.45

Day range

18.9019.62

52-week range

13.7527.30

Volume

1.23M0.77×

Mkt cap

3.03B

P/E ttm

—

Fwd P/E

-7.83

EPS ttm

-2.84

Div yield

0.00%

Earnings

Aug 6, 2026

From 52w high

−30.59%

Price Chart

Yahoo Finance · delayed

DNLIOct 12, 2026O 19.33H 19.62L 18.90C 18.95−0.50 (−2.57%)Vol 1.23M

SMA 5022.33
SMA 20021.12

1Y change +23.29% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

DNLI Denali Therapeutics Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −4.82%
1 month: −10.15%
3 months: −28.44%
6 months: −2.42%
Year to date: +14.78%
1 year: +23.29%

Valuation & ownership

Market cap: 3.03B
Enterprise value: 2.36B
P/E (ttm): —
Forward P/E: -7.83
PEG ratio: —
Price / book: 3.62
Price / sales (ttm): 840.49
EV / EBITDA: -4.48
EPS (ttm): -2.84
EPS (forward): -2.42
Beta (5y monthly): 1.02
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 159.85M
Float: 155.10M
Short % of float: 10.21%
Short ratio (days): 8.91
Held by insiders: 4.61%
Held by institutions: 101.28%
Avg volume (3m): 1.61M
50-day average: 22.33
200-day average: 21.12
52-week change: +23.29%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 34.6
vs 50-day SMA: −15.13%
vs 200-day SMA: −10.29%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 4.33%
Realised vol (20d, ann.): 44.1%
From 52-week high: −30.59%
From 52-week low: +37.82%

ANR

Analyst Consensus

16 analysts

Consensus

Strong buy

1.20 on a 1 (strong buy) – 5 (sell) scale

Mean target

35.75

+88.65% implied

Low 27.00Median 35.00High 42.00

Recommendation trend

Now19 / 1 / 0
1m ago19 / 1 / 0

DES

About Denali Therapeutics Inc.

Yahoo Finance profile

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 503
Headquarters: South San Francisco, CA, United States
Website: denalitherapeutics.com
Officers: Dr. Ryan J. Watts Ph.D. Co-Founder, President, CEO & Director
Dr. Alexander O. Schuth M.D., Ph.D.

SEAS

Seasonality · DNLI

2017–2026 · monthly returns

Strongest month Nov +13.71%Weakest month Mar −8.71%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	31.7	-2.6	-9.3	-2.5	12.4	22.2	-10.5	3.2	-13.0	-8.3			+14.8%
2025	14.3	-28.9	-17.9	22.5	-20.5	5.7	-1.1	10.4	-4.9	12.1	19.6	-15.2	−19.0%
2024	-25.4	23.5	3.7	-24.8	20.2	25.1	5.0	0.3	19.2	-10.9	-3.7	-18.5	−5.0%
2023	8.8	-10.3	-15.1	7.8	21.7	-2.3	-3.7	-18.8	-10.7	-8.7	-1.6	15.9	−22.8%
2022	-23.3	-4.9	-1.2	-26.0	2.1	21.2	15.6	-18.7	10.9	-6.5	11.3	-12.8	−37.6%
2021	-18.2	4.8	-20.5	5.8	5.2	23.4	-34.9	4.3	-5.2	-4.2	-4.3	-3.6	−46.8%
2020	33.0	-14.6	-11.4	24.8	27.3	-13.1	-3.1	36.2	12.3	19.4	42.5	37.4	+380.8%
2019	-7.7	14.2	6.7	5.4	-22.1	8.9	2.8	-15.7	-14.9	2.3	13.5	-2.1	−15.7%
2018	48.7	-1.6	-14.0	-6.1	4.1	-20.7	-17.4	55.9	10.7	-33.4	32.5	7.8	+32.1%
2017													—

INSD

Insider Activity · DNLI

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

89.9K shares

Sells, 6 months

18.7K shares

Net shares

+71.2K

Net change in insider shares

+1.00%

Date	Insider	Transaction	Shares	Value
Sep 3, 2026	Chin Peter ScottOfficer	Sale at price 22.29 per share.	1.7K	$36.87K
Sep 1, 2026	Thornberry Nancy A.Director	Sale at price 22.85 - 23.74 per share.	11.4K	$261.93K
Aug 31, 2026	Schuth Alexander OChief Operating Officer	Sale at price 23.44 per share.	2.8K	$64.88K
Aug 11, 2026	Watts Ryan JChief Executive Officer	Stock Gift at price 0.00 per share.	32.2K	—
Aug 10, 2026	Schuth Alexander OChief Operating Officer	Sale at price 25.07 per share.	2.9K	$71.63K
Jun 2, 2026	Flatley Jay TDirector	Stock Award(Grant) at price 0.00 per share.	6.4K	—
Jun 2, 2026	Klein Peter SDirector	Stock Award(Grant) at price 0.00 per share.	6.4K	—
Jun 2, 2026	Schenkein David PDirector	Stock Award(Grant) at price 0.00 per share.	6.4K	—
Jun 2, 2026	Krognes Steve EDirector	Stock Award(Grant) at price 0.00 per share.	6.4K	—
Jun 2, 2026	Cook Jennifer EDirector	Stock Award(Grant) at price 0.00 per share.	6.4K	—
Jun 2, 2026	Baker Bros Advisors, L.P.Beneficial Owner of more than 10% of a Class of Security	Stock Award(Grant) at price 0.00 per share.	12.8K	—
Jun 2, 2026	Thornberry Nancy A.Director	Stock Award(Grant) at price 0.00 per share.	6.4K	—
Jun 2, 2026	Van Hauwermeiren TimothyDirector	Stock Award(Grant) at price 0.00 per share.	6.4K	—
Jan 5, 2026	Schuth Alexander OChief Financial Officer	Sale at price 16.50 per share.	17.2K	$284.10K
Jan 5, 2026	Watts Ryan JChief Executive Officer	Sale at price 16.50 per share.	35.2K	$580.77K
Jan 1, 2026	Schuth Alexander OChief Operating Officer	Stock Award(Grant) at price 0.00 per share.	57.7K	—
Jan 1, 2026	Watts Ryan JChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	79K	—
Nov 3, 2025	Van Hauwermeiren TimothyDirector	Stock Award(Grant) at price 0.00 per share.	10.6K	—
Sep 2, 2025	Watts Ryan JChief Executive Officer	Stock Gift at price 0.00 per share.	50K	—
Aug 12, 2025	Ho CaroleOfficer	Sale at price 13.58 - 14.64 per share.	3.7K	$51.68K

DNLI

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

DNLI

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Denali Therapeutics Inc.

Seasonality · DNLI

Insider Activity · DNLI

Congress Trades · DNLI

Investors Holding DNLI

Investors Holding DNLI

Congress Trades · DNLI

Insider Activity · DNLI

Seasonality · DNLI

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Denali Therapeutics Inc.

Financial Snapshot

Earnings & Dividends

News